DIABETES PREVENTION TRIAL--TYPE I DIABETES

这是一项多中心方案，用于筛查高危患者 成为I型糖尿病患者的风险，并通过干预治疗来尝试 来预防糖尿病的发展。 最近， 使用胰岛细胞自身抗体（伊卡）来识别患有 在未来5年内有50%的机会发展为胰岛素依赖型糖尿病。 初级 胰岛素依赖型糖尿病患者的亲属患胰岛素依赖型糖尿病的风险增加10倍， 伊卡，这是本试验的目标人群。 患者 被归类为中度风险或高风险发展为胰岛素依赖型糖尿病的人 将提供两种随机干预方案之一。 那些 高风险类别的患者（超过50%的 在未来5年内发展为胰岛素依赖型糖尿病）将提供一个随机 无治疗与每日皮下注射长- 作用胰岛素

This is a multi-centered protocol to screen for patients at high risk of becoming type I diabetics, and to intervene with treatment to attempt to prevent the development of diabetes. It has recently become possible using islet cell autoantibodies (ICA) to identify individuals who have a 50 percent chance of developing IDDM within the next 5 years. Primary relatives of patients with IDDM have a tenfold increased risk of having ICA and this is the group that will be targeted in this trial. Patients who are classified as intermediate risk or high risk for developing IDDM will be offered one of two randomized intervention protocols. Those patients in the high risk category (greater than 50 percent of developing IDDM over the next 5 years) will be offered a randomized trial of no treatment versus daily subcutaneous injections of long- acting insulin.